1. 105PDetection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292. (23rd October 2018) Authors: Besse, B; Subbiah, V; Drilon, A; Shah, M; Wirth, L J; Bauer, T M; Velcheti, V; Lakhani, N; Boni, V; Solomon, B J; Johnson, M; Park, K; Patel, J; Cabanillas, M E; Sherman, E; Zhu, E; Gordon, K; Ebata, K; Tuch, B; Oxnard, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1087PAssociation of LIPI score with immune checkpoint inhibitors (ICI) outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (pts). (23rd October 2018) Authors: Herrera Gomez, R G; Mezquita, L; Auclin, E; Saleh, K; Baste Rotllan, N; Iacobs, M; Bursuc, S C; Mayache Badis, L; Ferrand, F R; Casiraghi, O; Temam, S; Breuskin, I; Tao, Y; Besse, B; Even, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1141PDAssociation between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. (23rd October 2018) Authors: Kfoury, M; Voisin, A-L; Najean, M; Champiat, S; Laghouati, S; Michot, J-M; Robert, C; Mateus, C; Albiges, L; Besse, B; Massard, C; Texier, M; Lambotte, O; Marabelle, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1206PIncidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy. (23rd October 2018) Authors: Baldini, C; Martin-Romano, P; Voisin, A-L; Danlos, F X; Champiat, S; Laghouati, S; Kfouri, M; Vincent, H; Nagera, C; Postel-Vinay, S; Varga, A; Ribrag, V; Besse, B; Hollebecque, A; Lambotte, O; Michot, J-M; Soria, J-C; Massard, C; Marabelle, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 1399PImpact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). (23rd October 2018) Authors: Peters, S; Shaw, A T; Besse, B; Felip, E; Solomon, B J; Soo, R A; Bearz, A; Gadgee, S M; Lin, C-C; Kao, S; Seto, T; Masters, E T; Abbattista, A; Clancy, J S; Thurm, H; Reisman, A; Camidge, D R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 1407PDerived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. (23rd October 2018) Authors: Mezquita, L; Arbour, K; Auclin, E; Saravia, D; Rizvi, H; Hendriks, L; Planchard, D; Park, W; Nadal, E; Ruffinelli Rodriguez, J C; Ponce, S; Audigier-Valette, C; Marilniello, A P; Zalcman, G; Majem, M; Schiavone, G; Dingemans, A-M C; Lopes, G; Hellmann, M D; Besse, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 1408PPrognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI). (23rd October 2018) Authors: Hendriks, L; Henon, C; Auclin, E; Mezquita, L; Ferrara, R; Audigier Valette, C; Mazieres, J; Lefebvre, C; Le Moulec, S; Duchemann, B; Le Pechoux, C; Botticella, A; Ammari, S; Gazzah, A; Caramella, C; Adam, J; Planchard, D; De Ruysscher, D; Dingemans, A-M C; Besse, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 1416PImmunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO). (23rd October 2018) Authors: Ferrara, R; Naigeon, M; Auclin, E; Duchemann, B; Cassard, L; Medhi, J; Boselli, L; Grivel, J; Desnoyer, A; Mezquita, L; Aboubakar, F; Hendriks, L; Planchard, D; Caramella, C; Remon, J; Ngocamus, M; Nicotra, C; Besse, B; Chaput, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 1446PManagement of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence. (23rd October 2018) Authors: Flippot, R; Auclin, E; Biondani, P; Le Rhun, E; Adam, J; Planchard, D; Caramella, C; Le Pechoux, C; Lacroix, L; Gazzah, A; Mezquita, L; Besse, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 17P Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients. (15th December 2019) Authors: Blanc-Durand, F; Auclin, E; Planchard, D; Aix, S Ponce; Hendriks, L; Sullivan, I G; Saravia, D; Routy, B; Castro, R Lopez; Pilotto, S; Aboubakar, F; Kassouf, E; Rodriguez, A; Martin, A Amores; Bluthgen, M V; Duchemann, B; Caramella, C; Nadal, E; Besse, B; Mezquita, L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗